MDT

86.54

-2.25%↓

121.03

-0.24%↓

VEEV

165.33

+3.83%↑

HQY

83.09

+3.06%↑

NEOG

9.51

+0.85%↑

MDT

86.54

-2.25%↓

121.03

-0.24%↓

VEEV

165.33

+3.83%↑

HQY

83.09

+3.06%↑

NEOG

9.51

+0.85%↑

MDT

86.54

-2.25%↓

121.03

-0.24%↓

VEEV

165.33

+3.83%↑

HQY

83.09

+3.06%↑

NEOG

9.51

+0.85%↑

MDT

86.54

-2.25%↓

121.03

-0.24%↓

VEEV

165.33

+3.83%↑

HQY

83.09

+3.06%↑

NEOG

9.51

+0.85%↑

MDT

86.54

-2.25%↓

121.03

-0.24%↓

VEEV

165.33

+3.83%↑

HQY

83.09

+3.06%↑

NEOG

9.51

+0.85%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Aperta

SettoreSettore sanitario

25.64 -2.36

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.54

Massimo

26.43

Metriche Chiave
By Trading Economics
Entrata	-85K 53M
Vendite	4.2M 153M
P/E Media del settore	14.869 66.418
EPS	0.68
Margine di Profitto	34.53
Dipendenti	182
EBITDA	612K 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+31.73% upside

Dividendi
By Dow Jones
Utili prossimi	6 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	107M 3.1B
Apertura precedente	28
Chiusura precedente	25.64

Notizie sul Sentiment di mercato

By Acuity

20%

80%

40 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 apr 2026, 23:36 UTC

Acquisizioni, Fusioni, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr 2026, 23:24 UTC

Azioni calde

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr 2026, 22:42 UTC

Acquisizioni, Fusioni, Takeovers

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr 2026, 21:32 UTC

I principali Market Mover

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr 2026, 23:54 UTC

Discorsi di Mercato

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr 2026, 22:54 UTC

Utili

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr 2026, 22:54 UTC

Utili

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr 2026, 22:14 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr 2026, 22:13 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr 2026, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr 2026, 22:12 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr 2026, 20:50 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

14 apr 2026, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 20:32 UTC

Azioni calde

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr 2026, 19:59 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 19:38 UTC

Utili

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 19:27 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr 2026, 19:21 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr 2026, 19:09 UTC

Acquisizioni, Fusioni, Takeovers

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr 2026, 18:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 apr 2026, 18:30 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

31.73% in crescita

Previsioni per 12 mesi

Media 34.5 USD 31.73%

Alto 35 USD

Basso 33 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

40 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.